Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers March 21, 2018
Pharmacy Choice - News - Generic Drugs - March 21, 2018

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 207     Next >>     Go To Page:

3/14/18 - "Reauthorization of Animal Drug User Fees: ADUFA (Animal Drug User Fee Act) and AGDUFA (Animal Generic Drug User Fee Act)."
Mike Topper, President of the American Veterinary Medical Association. A drug that is approved by the FDA has been shown through rigorous studies to be safe and effective for its labeled indication. Unfortunately, there simply are not enough FDA approved drugs for use in animals.
3/14/18 - House Energy and Commerce Committee News Release
"Under the proposed agreement, funding for the program would increase by approximately $6 million annually, all submissions must be electronic, the Center for Veterinary Medicine is required to begin implementation of the U.S.- E.U. good manufacturing practice Mutual Recognition Agreement for inspections of pharmaceutical manufacturing facilities,
3/14/18 - Sun Pharmaceutical Industries, Ltd., and Sun Pharma Global FZE; Withdrawal of Approval of Four Abbreviated New Drug Applications
FOR FURTHER INFORMATION CONTACT: Trang Tran, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1671, Silver Spring, MD 20993-0002, 240-402-7945, SUPPLEMENTARY INFORMATION: The holders of the applications listed in the table have informed FDA that these drug product
3/14/18 - Supply Of Biosimilar Etanercept Injection For Adult Use For Member Institutions The Control Group Under The Gcs Uniha - Etanb [TendersInfo (India)]
Short description: Provision of biosimilar etanercept injection for adult use for member institutions the control group under the GCS UniHA- ETANB Value excluding VAT: 1 euros. Deadline for receipt of tenders or requests to participate: April 10, 2018- 12:00. Language can be used in which tenders or requests to participate: French Major organizatio
3/13/18 - ADAMAS PHARMACEUTICALS INC FILES (8-K) Disclosing Other Events
On March 13, 2018, the U.S. Food and Drug Administration's New Paragraph IV Certifications list was updated to reflect that an abbreviated new drug application seeking authorization from the FDA to manufacture, use, or sell a generic version of GOCOVRI? extended release capsules, containing one or more certifications pursuant to 21 U.S.C. 355,
You should read the following discussion in conjunction with Item 1 A. and our audited consolidated financial statements included elsewhere in this annual report. Antares Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies.
3/13/18 - bc-graedon-pharmacy The People's Pharmacy: What is an authorized generic drug?
QUESTION: I want to share my experience trying to purchase an "authorized generic" drug. Our doctor did not know what that phrase meant, nor did any of the pharmacists we talked to about it. In the meantime, we had to go ahead and buy the brand-name drug at more than $500 for a 30- day supply.
3/13/18 - Biologics and Biosimilars Market 2018 Global Trends, Market Share, Industry Size, Growth, Opportunities and Forecast to 2023 adds "Biologics and Biosimilars Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023". adds "Biologics and Biosimilars Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023" reports to its database. This report provides in.
3/13/18 - Cantor Fitzgerald Names 8 Upcoming Biotech Catalysts
Mylan N.V. is scheduled to hold its investor day in New York City on April 11. A recently announced biosimilar Botox program with Revance Therapeutics Inc. A Humira biosimilar program. Its platform and pipeline.. A U.S. Patent Trial and Appeal Board oral hearing for Allergan plc Ordinary Shares' s Restasis is scheduled for April 3.
3/13/18 - Genocea Appoints Narinder Singh as SVP Pharmaceutical Sciences & Manufacturing [T-break Tech (Middle East)]
Prior to joining Genocea, Mr. Singh was Vice President of Drug Product Development and Manufacturing at Momenta Pharmaceuticals where he built an integrated drug product group to support Momentas expanding portfolio of biosimilars and novel biologics pipeline. Mr. Singh holds a B.Tech/ M.Tech in Biochemical Engineering and Biotechnology from Indian
3/13/18 - Global Biosimilars Market is Expected to Reach USD 13.1 Billion by 2024 | Hexa Research
"Fact-based market research, penetrating industry insights and validated forecasts to help you make better decisions for a stronger future" Research Report on Biosimilars Market Size, Growth, Regional Outlook, Application Analysis, Trends, Competitive Market Share and Forecasts, 2014- 2024| Hexa Research The global biosimilars market is expected to
3/13/18 - Hikma`s Advair generic delayed in the US [Syrian Arab News Agency]
Hikma Pharmaceuticals has been knocked back with the news that the FDA has delayed approval of its generic lung treatment for lack of data, it has emerged, which is good news for GlaxoSmithKline, manufacturer of the reference product Advair, who will be able to avoid increased competition in the space for a little while longer. Hikma confirmed it n
3/13/18 - Increasing Prevalence of Chronic Conditions Fuel the Europe Biosimilars Market: The Europe Biosimilars Market was worth USD 1,775.5 million in 2016 and estimated to be growing at a CAGR of 23.50%, to reach USD 6,109.1 million by 2022.
Hyderabad, India 03/13/2018 Biosimilars are not generics and are never treated as generics by producing companies and suppliers. Instead mentioned as bio-pharmaceuticals or follow-on biologics, biosimilars differ from generics within the entire producing process, right from the raw materials utilized in their producing. The Europe Biosimilars
3/13/18 - IQVIA Institute for Human Data Science Study: 10 Predictions for Innovation, Spending Drivers and Societal Value of Medicines that Will Transform Global Healthcare in 2018 and Beyond
Increasing use of real-world evidence and technology to improve access and outcomes from molecule-to-market across entire healthcare spectrum Modest global spending growth of 3-6 percent per year, estimated to exceed total cost of $1.44 trillion in 2022 worldwide Short-term drivers of drug value include increasing competition among biosimilars and.
3/13/18 - Rep. Francis Rooney (R-FL) News Release
Washington, DC- Congressman Francis Rooney co-sponsored H.R. 2212, the CREATES Act, which would promote drug price competition by making it easier for medicines whose patents have expired to be sold as less expensive generic versions. Congressman Rooney stated, "I stand with patients in their fight for affordable prescription pricing. The Congressi
3/13/18 - Sen. Daines Sponsors Bill to Increase Access to Lower-Cost Generic Drugs
Steve Daines, R- Montana, issued the following news release:. U.S. Senator Steve Daines today sponsored the Creating and Restoring Equal Access to Equivalent Samples Act, bipartisan legislation to combat brand-name drug manufacturers' attempts to delay competition from more affordable generic drugs. "I couldn't be happier that Senator Daines is ad
3/13/18 - Teligent, Inc. to Present at the Oppenheimer 28th Annual Healthcare Conference on Tuesday March 20, 2018
Teligent, Inc., a New Jersey based specialty generic pharmaceutical company, will be presenting at the Oppenheimer 28 th Annual Healthcare Conference. Jason Grenfell-Gardner, President and CEO and Damian Finio, Chief Financial Officer of Teligent, Inc. will present on Tuesday March 20 th at 8:00 a.m. ET. Contact: Damian Finio Teligent, Inc. 336-9
3/13/18 - Waverley Pharma Announces Filing of Marketing Authorization Application in Select European Union Countries [Syrian Arab News Agency]
Waverley Pharma Inc., an emerging Canadian pharmaceutical company, is pleased to announce that its wholly-owned Irish Subsidiary Waverley Pharma Europe Limited, has submitted a Marketing Authorization application through the European Union`s De-Centralized Procedure for an anti-cancer generic drug. The product was in-licensed and developed under a.
3/12/18 - Pricing headwinds to linger on, to mute Pharma topline in FY19
Domestic pharmaceutical industry, the largest producer of generics drugs in the world, is expected to continue to face the pricing headwinds that they had faced in FY18 mainly in the US, muting its revenue growth, says a report. We expect generic drug pricing headwinds, witnessed in FY18 mainly in the US, to continue over FY19 and keep the secto
3/12/18 - Amneal Pharmaceuticals and Impax Laboratories to Present at the Barclays Global Healthcare Conference
BRIDGEWATER- Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. today announced that they will jointly present at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel in Miami, Florida on Tuesday, March 13, 2018 at 2:35 p.m. ET. Paul Bisaro, President and CEO of Impax, Bryan Reasons, Senior Vice President and Chief Financia
3/12/18 - Biologics and Biosimilars Market 2018 Global Trends, Market Share, Industry Size, Growth, Opportunities and Forecast to 2023
"Biologics and Biosimilars Market" adds Biologics and Biosimilars Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023. adds "Biologics and Biosimilars Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023" reports to
3/12/18 - Biosimilar Industry Demand, Market Scope, Growth Analysis, Research Forecasting 2018: Biosimilar Market By Product (Recombinant Non-Glycosylated Proteins, Recombinant Peptides, Recombinant Glycosylated Proteins),Types (Human growth hormone, Erythropo
Pune, India 03/12/2018 The Global Biosimilar Market accounted to USD 3.5 billion in 2016 growing at a CAGR of 27.0% during the forecast period of 2017 to 2024. The upcoming market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.. Numerous regulatory authorities which i
3/12/18 - Investigators at Janssen Research & Development LLC Zero in on Concerta Therapy (Medication changes after switching from CONCERTA? brand...
By a News Reporter-Staff News Editor at Pharma Business Week Data detailed on Drugs and Therapies- Concerta Therapy have been presented. According to news reporting originating in Titusville, New Jersey, by NewsRx journalists, research stated, "Observational studies of switching from branded to generic formulations of the same drug substance ofte
3/12/18 - Mylan to Bring a Biosimilar of BOTOX to the Market Through a Collaboration and License agreement with Revance Therapeutics
By a News Reporter-Staff News Editor at Pharma Business Week Mylan N.V. and Revance Therapeutics, Inc. announced a global collaboration and license agreement for the development and commercialization of a proposed biosimilar to BOTOX . BOTOX is the market-leading neuromodulator approved for the treatment of multiple indications and usage in the
3/12/18 - New Therapeutics Research Findings from Tel Aviv University Outlined (Error in Drugs Consumption Among Older Patients)
By a News Reporter-Staff News Editor at Clinical Trials Week Investigators publish new report on Drugs and Therapies- Therapeutics Research. According to news reporting originating in Tel Aviv, Israel, by NewsRx journalists, research stated, "The cost effectiveness of generic drugs has promoted their use worldwide. The news reporters obtained a q
Articles(s): 1 - 25 of 207     Next >>     Go To Page:

© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement